Announced details
Advanced endometrial cancer with disease progression after platinum-based chemotherapy and anti-PD-(L)1 immunotherapy. Solid tumors.
30 registered patients, 11 responders, objective response rate of 36.7%, ORR of 57.1% among patients not previously treated with lenvatinib, and no Grade 4 or Grade 5 treatment-related adverse events.
30 patients enrolled in the dose-expansion cohort of the Phase Ib/II clinical trial. Whether this is cumulative or as of a specific point in time: Not disclosed.
Relationship involving the joint creation of E7386. Eisai is conducting the clinical trial. Capital and personnel relationships: Not disclosed.
Headquartered in Bunkyo-ku, Tokyo. Conducts clinical trials of E7386 and lenvatinib. Pharmaceutical company that developed lenvatinib. Other attributes: Not disclosed.
NCT04008797 (clinical trial registration number), DOI: 10.1016/j.eclinm.2026.104206. Registration date and expiration date: Not disclosed.
株式会社PRISM BioLab headquarters: 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa, Shonan iPark. Eisai headquarters: Bunkyo-ku, Tokyo.
Impact on financial performance is not disclosed.
The company does not address Contract Value / Offering price.
eClinicalMedicine (2026;100:104206), The Lancet Group, ClinicalTrials.gov (NCT04008797)
| Item | Details |
|---|---|
| Names of Products / Services Covered | E7386, Lenvatinib (brand name: LENVIMA®), Combination therapy with E7386 and lenvatinib |
| Counterparty | Eisai Co.,Ltd. |
| Counterparty overview | Headquartered in Bunkyo-ku, Tokyo. Conducts clinical trials of E7386 and lenvatinib. Pharmaceutical company that developed lenvatinib. Other attributes: Not disclosed. |
| Relationship with the Company | Relationship involving the joint creation of E7386. Eisai is conducting the clinical trial. Capital and personnel relationships: Not disclosed. |
| Applicable area | Advanced endometrial cancer with disease progression after platinum-based chemotherapy and anti-PD-(L)1 immunotherapy. Solid tumors. |
| Registration number and expiry date | NCT04008797 (clinical trial registration number), DOI: 10.1016/j.eclinm.2026.104206. Registration date and expiration date: Not disclosed. |
| Location | 株式会社PRISM BioLab headquarters: 2-26-1 Muraoka-Higashi, Fujisawa, Kanagawa, Shonan iPark. Eisai headquarters: Bunkyo-ku, Tokyo. |
| Quantitative Effects | 30 registered patients, 11 responders, objective response rate of 36.7%, ORR of 57.1% among patients not previously treated with lenvatinib, and no Grade 4 or Grade 5 treatment-related adverse events. |
| Usage history | 30 patients enrolled in the dose-expansion cohort of the Phase Ib/II clinical trial. Whether this is cumulative or as of a specific point in time: Not disclosed. |
| Impact on Business Performance | Impact on financial performance is not disclosed. |
| Source | eClinicalMedicine (2026;100:104206), The Lancet Group, ClinicalTrials.gov (NCT04008797) |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The paper was published in a peer-reviewed, open-access medical journal, making the trial results publicly available. The paper explains that the trial showed a manageable safety profile and antitumor activity, providing useful findings for advancing the dose-optimization part.